Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age, endocrine therapy persistence, and recurrence risk in hormone receptor-positive early breast cancer: clarifying a long-standing clinical question.

Chinese clinical oncology·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

Stability of potato glycoalkaloids under heating conditions - Reactions with fatty acids.

Current research in food science·2026
Same author

AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

The community engagement and empowerment cycle: FAIRagro's framework to foster cultural change towards FAIR RDM practices in agrosystem science and beyond.

Journal of integrative bioinformatics·2026

Related Experiment Video

Updated: Mar 16, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.7K

Palbociclib - from Bench to Bedside and Beyond.

Marcus Schmidt1

  • 1Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, Germany.

Breast Care (Basel, Switzerland)
|August 6, 2016
PubMed
Summary
This summary is machine-generated.

Palbociclib, a CDK4/6 inhibitor, combined with endocrine therapy, shows efficacy in advanced hormone receptor-positive breast cancer. Ongoing trials will determine its role in early-stage disease.

Keywords:
Breast cancerCDK4/6Estrogen receptorPD 0332991Palbociclib

More Related Videos

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications
06:42

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

Published on: September 2, 2025

707
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Experiment Videos

Last Updated: Mar 16, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.7K
Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications
06:42

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

Published on: September 2, 2025

707
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Hormone receptor-positive breast cancer treatment relies on endocrine therapy.
  • Cell cycle regulation, particularly the G1-S transition controlled by cyclin-dependent kinases (CDKs), is crucial.
  • CDK4/6 are key regulators, making them therapeutic targets.

Purpose of the Study:

  • To review preclinical data and early clinical trials of palbociclib.
  • To highlight palbociclib's FDA approval for advanced hormone receptor-positive, HER2-negative breast cancer.
  • To outline ongoing clinical trials of palbociclib in various breast cancer stages.

Main Methods:

  • Review of preclinical studies on CDK4/6 inhibition.
  • Analysis of early-phase clinical trial data for palbociclib.
  • Summary of current clinical trial designs involving palbociclib.

Main Results:

  • Palbociclib demonstrated significant clinical development.
  • Accelerated FDA approval granted for first-line treatment with letrozole in advanced HR+/HER2- breast cancer.
  • Palbociclib plus endocrine therapy is an effective option for advanced disease.

Conclusions:

  • CDK4/6 inhibition with palbociclib is efficacious in advanced HR+/HER2- breast cancer.
  • Palbociclib combined with endocrine therapy represents a significant advancement.
  • Further research is needed to establish palbociclib's role in early breast cancer treatment.